Synonyms: ANG-3070 | ANG3070 | Example 1 [WO2013112959A1]
Compound class:
Synthetic organic
Comment: We obtained the chemical structure for ansornitinib from the WHO's proposed INN list 127 (21 July 2022). In this document it was described as a tyrosine kinase kinase inhibitor. Ansornitinib may be ANG-3070, an oral tyrosine kinase inhibitor that was developed by Angion Biomedica for anti-fibrotic potential in kidney diseases, such as focal segmental glomerulosclerosis and immunoglobulin A nephropathy. Clinical trial of ANG-3070 was terminated in June 2022, following an unexpected and dangerous decline in kidney function in a patient who received the drug treatment. Development for idiopathic pulmonary fibrosis appears to be continuing.
|
|
References |
1. Panicker B, Mishra MK, Jung D, Oeheln LJWM, Lim DS. (2013)
Antifibrotic compounds and uses thereof. Patent number: WO2013112959A1. Assignee: Angion Biomedica Corp.. Priority date: 26/01/2012. Publication date: 01/08/2013. |